Vibose® is the preparation of voglibose. Voglibose acts by inhibition of alpha- glucosidase, an enzyme responsible to breakdown carbohydrate and facilitate the absorption of monosaccharide, i.e. glucose, fructose. Thus, voglibose delays the absorption as well as digestion of dietary carbohydrates. Voglibose is indicated for improvement of postprandial hyperglycemia in diabetes mellitus only when diet and/or exercise or oral hyperglycemic drug or Insulin preparation in addition to diet and/or exercise does not result in adequate glycemic (Glycemic) control. The drug is taken just before meals to prevent the postprandial hyperglycemia seen in diabetics. This type of agent can be considered a drug of first choice in overweight diabetic patients
Vibose Tablet 0.3 mg
Normal Adult Dose: Usually, Voglibose tablets are orally administered in a single dose of 0.2 mg, 3 times a day, before each meal. If the effect is not sufficient, the quantity of a single dose may be increased up to 0.3 mg.
Pediatrics: The safety and effectiveness of Voglibose in children has not been established.
Geriatrics: Since elderly patients generally have a physiological hypofunction, it is desirable that such caution be taken as starting the administration at a lower dose (eg, 0.1 mg at a time). Furthermore, this drug should be carefully administered under close observation, through the course of the disease condition, with careful attention to the blood sugar level and the onset of gastrointestinal symptoms.